Monopar Therapeutics (MNPR) Stock Price, News & Analysis

Company Overview

Monopar Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development. Monopar’s lead programs employ its PRIT platform to address both hematologic malignancies and solid tumors, and the company is also exploring antibody-drug conjugate approaches to expand its immunotherapeutic offerings. Through these efforts, Monopar seeks to deliver targeted, high-potency treatments that can overcome resistance and improve patient outcomes.

Founded in 2018 and headquartered in Newton, Massachusetts, Monopar Therapeutics has established research collaborations and licensing agreements to advance its proprietary technologies. The company holds global rights to its PRIT platform, which was initially developed through academic partnerships, and maintains research operations in key U.S. life-science clusters. Monopar continues to strengthen its development capabilities through strategic collaborations with academic institutions and contract research organizations.

Monopar is led by a management team with extensive experience in oncology drug development, radiopharmaceutical manufacturing and clinical operations. The leadership team combines scientific expertise and industry know-how to advance the company’s pipeline and navigate regulatory pathways. Together, they are working to bring next-generation targeted therapies to patients with high-need cancers.

Key Stats

• Today's Range: $118.04 to $124.42
• 50-Day Range: $59.10 to $120.21
• 52-Week Range: $29.18 to $124.82
• Volume: 223,298 shs
• Average Volume: 299,624 shs
• Market Capitalization: $798.59 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $112.08
• Consensus Rating: Buy

Monopar Therapeutics Stock Analysis - MarketRank™

Monopar Therapeutics scored higher than 25% of companies evaluated by MarketBeat, and ranked 796th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Monopar Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.07, and is based on 3 strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.

Downside Risk

Monopar Therapeutics has a consensus price target of $112.08, representing about 6.0% downside from its current price of $119.21.

Amount of Analyst Coverage

Monopar Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Monopar Therapeutics are expected to decrease in the coming year, from ($2.82) to ($4.30) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Monopar Therapeutics is -62.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Monopar Therapeutics is -62.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Monopar Therapeutics has a P/B Ratio of 5.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

22.49% of the float of Monopar Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Monopar Therapeutics has a short interest ratio ("days to cover") of 5.94.

Change versus previous month

Short interest in Monopar Therapeutics has recently decreased by 10.49%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Monopar Therapeutics does not currently pay a dividend.

Dividend Growth

Monopar Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: 0.47

News Sentiment

Monopar Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Monopar Therapeutics this week, compared to 4 articles on an average week.

MarketBeat Follows

Only 1 people have added Monopar Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Monopar Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.70% of the stock of Monopar Therapeutics is held by insiders.

Percentage Held by Institutions

1.83% of the stock of Monopar Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 8/09/2026
• Next Earnings (Estimated): 8/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MNPR
• CIK: 1645469
• Web: www.monopartx.com
• Phone: 847-388-0349
• Fax: N/A
• Employees: 10
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Monopar Therapeutics: $112.08
• High Price Target: $125.00
• Low Price Target: $74.00
• Potential Upside/Downside: -6.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.07
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.72 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -12.84%
• Return on Assets: -12.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 56.04
• Quick Ratio: 56.04

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $20.62 per share
• Price / Book: 5.78

Miscellaneous

• Outstanding Shares: 6,699,000
• Free Float: 6,049,000
• Market Cap: $798.59 million
• Optionable: Not Optionable
• Beta: 1.47